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Abstract
Introduction: Ghrelin and obestatin derive from the same precursor. Ghrelin is an energy balance regulator and obestatin’s role in metabolic 
processes cannot be excluded. The aim of this study was to assess plasma ghrelin and obestatin changes in thyroid disorders.
Material and methods: We evaluated plasma ghrelin and obestatin levels in severe hypothyroidism, hypothyroidism after thyreoidectomy 
and 4-weeks L-thyroxine withdrawal, and in hyperthyroidism. We also re-evaluated plasma ghrelin and obestatin levels in patients with 
severe hypothyroidism and hyperthyroidism after treatment.
Results: Severe hypothyroidism was associated with a reasonably high ghrelin level (p = 0.055) and hyperthyroidism with a significantly 
lower ghrelin level (p = 0.01) compared to healthy subjects. Ghrelin in hypothyroid patients after L-thyroxine withdrawal did not differ 
from the control group (p = 0.3). Compared to healthy subjects, obestatin level in hyperthyroidism was decreased (p = 0.03) and did not 
differ in severe hypothyroidism due to thyroiditis (p = 1) or after L-thyroxine withdrawal (p = 0.6). Ghrelin and obestatin levels corre-
lated positively. Both peptides levels correlated positively with TSH and negatively with free thyroid hormones. In patients with severe 
hypothyroidism, ghrelin level significantly decreased after treatment (p < 0.01) and in hyperthyroid patients significantly increased after 
treatment (p = 0.04). There were no significant changes in obestatin levels in hypo- or hyperthyroid patients after treatment.
Conclusions: Plasma ghrelin changes and its correlation with TSH and thyroid hormones may indicate a compensatory role of ghrelin in 
metabolic disturbances associated with thyroid dysfunction. The positive correlation between ghrelin and obestatin levels may suggest 
a modulatory role of obestatin in these processes. (Endokrynol Pol 2012; 63 (6): 456–462)
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Streszczenie
Wstęp: Ghrelina i obestatyna są peptydami pochodzącymi z tego samego prekursora. Ghrelina w istotny sposób wpływa na utrzymanie 
równowagi energetycznej organizmu. Rola obestatyny w tym zakresie nie jest wykluczona. Celem pracy była ocena stężeń ghreliny 
i obestatyny w osoczu chorych z zaburzeniami czynności tarczycy.
Materiał i metody: Badano stężenia ghreliny i obestatany u chorych z ciężką niedoczynnością tarczycy, u chorych po strumektomii 
całkowitej i 4-tygodniowym odstawieniu L-tyroksyny oraz u chorych z nadczynnością tarczycy. Porównano stężenia obu peptydów 
u pacjentów z nadczynnością tarczycy i ciężką niedoczynnością tarczycy przed i po leczeniu.
Wyniki: W porównaniu z grupą kontrolną u chorych z ciężką niedoczynnością tarczycy wykazano wysokie stężenie ghreliny (p = 0,055), 
a u chorych z nadczynnością tarczycy — obniżone (p = 0,01). Stężenie ghreliny u chorych po tyreoidektomii i odstawieniu L-tyroksyny 
nie różniło się od wartości stwierdzanych u osób zdrowych (p = 0,3). Stężenie obestatyny w nadczynności tarczycy było istotnie obniżone 
(p = 0,03). W obu rodzajach niedoczynności tarczycy nie różniło się istotnie od grupy kontrolnej. Stężenia ghreliny i obestatyny korelo-
wały dodatnio. Stężenia obu peptydów korelowały dodatnio z TSH, a ujemnie ze stężeniem wolnych hormonów tarczycy. Po leczeniu 
u pacjentów z ciężką niedoczynnością tarczycy stężenie ghreliny istotnie obniżało się (p < 0,01), a u chorych z nadczynnością tarczycy 
wzrastało (p = 0,04). Nie wykazano istotnych różnic w stężeniu obestatyny przed i po leczeniu w żadnej z tych grup.
Wnioski: Zmiany stężenia ghreliny i korelacje z parametrami czynności tarczycy mogą wskazywać na kompensacyjną rolę ghreliny 
w zaburzeniach metabolicznych towarzyszących zaburzeniom czynności tarczycy. Dodatnia korelacja pomiędzy stężeniem ghreliny 
i obestatyny może sugerować udział obestatyny w tych procesach. (Endokrynol Pol 2012; 63 (6): 456–462)
Słowa kluczowe: ghrelina, obestatyna, tarczyca, niedoczynność tarczycy, nadczynność tarczycy
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Introduction
Ghrelin and obestatin are two peptides deriving from 
the same precursor — preproghrelin [1–3]. Due to their 
common origin, both peptides are of particular inter-
est regarding their compatible or opposite biological 
functions.
Ghrelin was discovered as the first endogenous 
ligand for growth hormone secretagogue receptor 
(GHS-R) [1] and proved to be a strong, dose-dependent 
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stimulator of GH release [4]. However, it also plays an 
important role in the regulation of metabolic processes. 
Ghrelin stimulates appetite by binding its receptors 
in the hypothalamus and increasing the release of 
orexigenic peptides (neuropeptide Y [NPY] and Agouti-
related peptide [AgRP] [5, 6], acts as an adipogenic fac-
tor [7], accelerates gastric emptying [8, 9], and reduces 
energy expenditure [10].
There are two main forms of ghrelin. Acylated 
28-amino acid peptide (posttranslationally n-octanoylat-
ed at the third residue — Ser 3) is able to bind its receptor 
and exert biological activity [1, 11]. Unacylated ghrelin, 
previously considered to be inactive, has been recently 
shown to have some biological function [3].
Ghrelin is predominantly produced in neuroendo-
crine cells (X/A cells) of the gastric mucous membrane 
[1, 12]. However, its expression has been demonstrated 
also in the hypothalamus, hypophysis, small and large 
intestine, liver, pancreas, thyroid and many other central 
and peripheral organs [13–16]. Growth hormone secre-
tagogue receptors (type GHS-R1a and GHS-R1b) are 
widely expressed as well [13, 16–18]. Type GHS-R1a has 
been described as the functional ghrelin receptor [13].
The regulation of ghrelin release is based on food 
intake rhythm i.e. fasting increases, and food intake 
reduces, ghrelin release [19]. Considering long-term 
metabolic disturbances, obesity is associated with low 
plasma ghrelin level [20]. Negative energy balance states 
such as cachexia, anorexia nervosa and bulimia increase 
ghrelin production [21–23].
Similarly to ghrelin, obestatin is predominantly pro-
duced in the stomach [24]. Its expression has been also 
demonstrated in the small and large intestine, pancreas, 
mammary ducts and in the thyroid gland [15, 25, 26]. 
Obestatin has been initially shown to reduce food intake 
and body weight gain and to suppress intestinal motility 
[2]. However, since its discovery, the studies describing 
the physiology and function of obestatin have been in 
constant opposition to those claiming that it does not 
have any biological activity and remains only a ghrelin-
associated peptide [27–29]. Obestatin receptor has not 
been described yet [30]. Nevertheless, since obestatin 
level is reduced in obesity and increased in anorexia 
nervosa [31, 32], its direct or indirect influence on food 
intake and body weight cannot be excluded.
Ghrelin’s involvement in energy balance regulation 
and the possible role of obestatin in this mechanism sug-
gests a potential correlation between both peptides and 
thyroid function. It is well known that metabolic dis-
turbances influence thyroid hormones release and, on 
the other hand, hyper- and hypothyroidism increases 
and decreases the rate of metabolism respectively. The 
expression of ghrelin and its receptors in the thyroid 
gland has been already confirmed [13–18]. Furthermore, 
it has been demonstrated that exogenous ghrelin is 
strongly uptaken in the thyroid [33]. Obestatin also has 
been demonstrated in thyroid tissue [15, 26]. Therefore, 
a relationship between thyroid function and ghrelin and 
obestatin production is worth considering.
Most of the studies have revealed that hypothy-
roidism is associated with high ghrelin level [34–36] 
that decreases after treatment [35]. However, some 
authors did not notice any differences [37–40] or actu-
ally observed low plasma ghrelin levels [41, 42]. Hy-
perthyroidism, despite increased appetite and weight 
loss, was surprisingly associated mostly with decreased 
ghrelin concentration [34, 36–38, 43–47], that rose after 
treatment [37, 38, 43, 44, 46, 47]. Obestatin changes in 
thyroid dysfunction have so far been analysed only in 
one study. Kosowicz et al. revealed that hypothyroidism 
and hyperthyroidism are respectively associated with 
high and low obestatin levels [36].
The aim of this study was to evaluate ghrelin and 
obestatin plasma levels in patients with hypothyroid-
ism and hyperthyroidism and to assess for the first time 
the changes of both peptides in hypothyroidism and 
hyperthyroidism before and after treatment.
Material and methods
The study group consisted of:
 — 16 patients with severe hypothyroidism (15 women, 
one man) due to Hashimoto’s thyroiditis or after 
radioiodine treatment (due to toxic goitre or Graves’ 
disease in the past);
 — 24 patients with hypothyroidism (23 women, one 
man), who had undergone total thyroidectomy due 
to differentiated thyroid cancer and were examined 
after 4-week L-thyroxine withdrawal — examination 
performed during prearranged qualification for 
radioiodine treatment, that required L-thyroxine 
withdrawal (clinical symptoms of hypothyroidism 
poorly manifested);
 — 22 patients with hyperthyroidism (19 women, three 
men) due to Graves’ disease or toxic goitre (typical 
clinical image of hyperthyroidism);
 —  21 euthyroid volunteers (18 women, three men) — 
the control group.
Blood samples for plasma ghrelin and obestatin 
assessment were collected from antecubital veins after 
a ten-hour fast and placed into polyethylene tubes 
containing plasma enzymes inhibitors (aprotinin and 
EDTA). Total plasma ghrelin levels were measured 
in duplicate with a commercially available radioim-
munological assay (RIA) kit (Phoenix Pharmaceuticals 
Inc.). Plasma obestatin levels were measured in plasma 
extracts as recommended by the manufacturer with 
a commercially available RIA kit (Phoenix Pharmaceuticals 
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Inc.). Radioactivity of the samples was measured in an 
automatic LKB-Wallace gamma counter. The assessment 
of obestatin levels in plasma extracts was technically 
complicated and could be completed in 71 probes. The 
difficulty appeared especially in the evaluation of hypo-
thyroidism before and after treatment. The techniques 
of plasma ghrelin and obestatin measurement and 
difficulties associated with the assessment have been 
already described [48].
Free thyroxine (fT4), free triiodothyronine (fT3) and 
thyrotropin (TSH) levels were assessed using an elec-
trochemiluminescence method. Serum anti-thyroglobulin 
(aTg), anti-thyroid peroxidase antibodies (aTPO) and 
anti-TSH-receptor antibodies (TRAb) were measured 
by radioimmunoassay (RIA).
In ten hyperthyroid patients, ghrelin and obestatin 
plasma levels were assessed once more, when they became 
clinically and biochemically euthyroid after treatment. 
Similarly, in nine hypothyroid patients with Hashimoto’s 
or radioiodine-induced thyroiditis, the examination was 
performed again after treatment with L-thyroxine.
Hyperthyroid, hypothyroid and euthyroid groups 
were compared using a non-parametric Kruskal-Wallis 
test. The changes in ghrelin and obestatin level before 
and after treatment were analysed with Wilcoxon 
signed-ranks test. Correlations were assessed by use of 
Spearman’s rank correlation coefficient.
The study was conducted with the permission of 
Poznan University of Medical Sciences’ Ethical Committee. 
The analyses were performed in the laboratories of the 
Department of Endocrinology, Metabolism and Internal 
Medicine of Poznan University of Medical Sciences.
Results
The clinical and biochemical characteristics of the study 
group are presented in Table I.
The study revealed that in severe hypothyroidism 
due to Hashimoto thyroiditis or after radioiodine treat-
ment, plasma ghrelin level was high in comparison to 
the control group with a p-value very close to statisti-
cal significance (p = 0.055). Hyperthyroid patients had 
a significantly lower plasma ghrelin level compared 
to healthy subjects (p = 0.01), to hypothyroid patients 
with Hashimoto’s thyroiditis or after radioiodine treat-
ment (p < 0.001), and to hypothyroid patients after 
L-thyroxine withdrawal (p < 0.001). Plasma ghrelin 
level in hypothyroid patients after total thyroidectomy 
and L-thyroxine withdrawal did not differ from values 
observed in healthy subjects (p = 0.3) (Fig. 1).
Obestatin level in hyperthyroid patients was sig-
nificantly decreased compared to healthy subjects 
(p = 0.03), to patients with thyroiditis (p < 0.01), and to 
patients after L-thyroxine withdrawal (p < 0.001) (Fig. 2). 
Compared to the control group, there was no difference 
in obestatin level in hypothyroidism due to Hashimoto’s 
thyroiditis or after radioiodine treatment (p = 1), or 
hypothyroidism after L-thyroxine withdrawal (p = 0.6).
In the whole study group, including patients with 
thyroid disorders and the control group, ghrelin and 
Table I. The clinical and biochemical characteristics of the patients (1) with hyperthyroidism, (2) with hypothyroidism due 
to Hashimoto’s thyroiditis or after radioiodine treatment, (3) with hypothyroidism after thyreoidectomy and L-thyroxine 
withdrawal, and (4) of the control group (normal ranges: TSH 0.27–4.2 uIU/mL; fT4 11.5–21 pmol/L; fT3 3.93–7.70 pmol/L)
Tabela. I. Charakterystyka kliniczna i biochemiczna (1) pacjentów z nadczynnością tarczycy, (2) pacjentów z ciężką 
niedoczynnością tarczycy z powodu zapalenia tarczycy typu Hashimoto lub po leczeniu radiojodem, (3) pacjentów z 
niedoczynnością tarczycy po tyreoidektomii i odstawieniu L-tyroksyny i (4) grupy kontrolnej (wartości referencyjne: TSH 
0.27–4.2 uIU/ml; fT4 11.5–21 pmol/l; fT3 3.93–7.70 pmol/l)
Hyperthyroidism Hypothyroidism 
(Hashimoto’sthyroiditis or after 
radioiodine treatment)
Hypothyroidism 
(L-thyroxine withdrawal)
Control group
Number of patients 22 16 24 21
Sex (F/M) 19/3 15/1 23/1 18/3
Age (years) 41 ± 14 38 ± 14 41 ± 14 33 ± 7
BMI [kg/m2] 22.3 ± 3.7 23.2 ± 3.6 23.3 ± 2.3 23 ± 2.7
TSH [uIU/mL] 0.006 ± 0.001 82.1 ± 27.1 82.7 ± 22 1.96 ± 0.85
fT4 [pmol/L] 38.7 ± 18.7 3.9 ± 3.4 2.1 ± 0.9 16.2 ± 1.8
fT3 [pmol/L] 15.8 ± 8.6 1.6 ± 1.4 0.9 ± 0.4 4.99 ± 0.6
Ghrelin [pg/mL] 205.9 ± 89.3 631.1 ± 270.6 522.5 ± 276.6 347.6 ± 121.3
obestatin [pg/mL] 21.3 ± 5.2 31.2 ± 7.9 30.4 ± 3.5 27.4 ± 3.6
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obestatin correlated positively (r = 0.8, p < 0.05). 
Furthermore, both peptides correlated positively with TSH 
(ghrelin r = 0.6, p < 0.05; obestatin r = 0.6, p < 0.05) 
and negatively with fT3 (ghrelin r = –0.7, p < 0.05; 
obestatin r = –0.6, p < 0.05) and fT4 levels (ghrelin r = 
= –0.7, p < 0.05; obestatin r = –0.6, p < 0.05).
The analysis of plasma ghrelin levels in patients 
with severe hypothyroidism after treatment revealed 
a significant decrease in peptide concentration (p < 
< 0.01) (Table II, Fig. 3). In patients with hyperthyroid-
ism who became euthyroid after treatment, we observed 
a significant increase in plasma ghrelin level (p = 0.04) 
(Table II, Fig. 4). There was no significant difference 
between plasma obestatin level in hypo- or hyperthy-
roid patients before and after treatment (p = 0.7 and 
p = 0.4, respectively).
Table II. The clinical and biochemical characteristics of hypothyroid patients (with Hashimoto’s thyroiditis or after radioiodine 
treatment) and of hyperthyroid patients before and after treatment (normal ranges: TSH 0.27–4.2 uIU/mL; fT4 11.5–21 pmol/L; fT3 
3.93–7.70 pmol/L)
Tabela II. Charakterystyka kliniczna i biochemiczna pacjentów z niedoczynnością tarczycy (z powodu zapalenia tarczycy typu 
Hashimoto lub po leczeniu radiojodem) oraz pacjentów z nadczynnością tarczycy przed i po leczeniu (wartości referencyjne: 
TSH 0.27–4.2 uIU/ml; fT4 11.5–21 pmol/l; fT3 3.93–7.70 pmol/l)
Hypothyroidism (Hashimoto’s thyroiditis or after 
radioiodine treatment)
Hyperthyroidism
Before treatment After treatment Before treatment After treatment
TSH [uIU/mL] 83.3 ± 26.2 1.7 ± 1.7 0.005 ± 0.001 1.1 ± 0.6
fT4 [pmol/L] 4.5 ± 3.5 22.5 ± 3.1 44.2 ± 24.5 19.7 ± 5.2
fT3 [pmol/L] 1.9 ± 1.7 4.9 ± 0.9 18.4 ± 11.2 4.5 ± 0.7
BMI [kg/m2] 24.3 ± 4 22.5 ± 3.9 20.4 ± 2.5 21.4 ± 2
Ghrelin [pg/mL] 652.9 ± 247.8 372.1 ± 124.6 206.7 ± 90.6 321.1 ± 119.9
Obestatin [pg/mL] 33.5 ± 9.5 29.4 ± 2.7 22.8 ± 6 27.6 ± 6.8
Figure 1. Plasma ghrelin levels in the control group, in patients 
with hypothyroidism due to Hashimoto’s thyroiditis or after 
radioiodine treatment — ‘Hypothyroidism due to thyroiditis’, 
in patients with hypothyroidism after thyreoidectomy and 
L-thyroxine withdrawal and in hyperthyroid patients
Rycina 1. Stężenie ghreliny w osoczu osób bez zaburzeń czynności 
tarczycy, w niedoczynności tarczycy z zapaleniem tarczycy typu 
Hashimoto lub po leczeniu radiojodem — ‘Hypothyroidism due 
to thyroiditis’, w niedoczynności tarczycy po tyreoidektomii 
i odstawieniu L-tyroksyny oraz w nadczynności tarczycy
Figure 2. Plasma obestatin levels in the control group, in patients 
with hypothyroidism due to Hashimoto’s thyroiditis or after 
radioiodine treatment — ‘Hypothyroidism due to thyroiditis’, 
in patients with hypothyroidism after thyreoidectomy and 
L-thyroxine withdrawal and in hyperthyroid patients
Rycina 2. Stężenie obestatyny w osoczu osób bez zaburzeń czynności 
tarczycy, w niedoczynności tarczycy z zapaleniem tarczycy typu 
Hashimoto lub po leczeniu radiojodem — ‘Hypothyroidism due 
to thyroiditis’, w niedoczynności tarczycy po tyreoidektomii 
i odstawieniu L-tyroksyny oraz w nadczynności tarczycy
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Figure 3. Plasma ghrelin levels in hypothyroid patients (with 
Hashimoto’s thyroiditis or after radioiodine treatment) before 
(ghrelin 1) and after treatment (ghrelin 2)
Rycina 3. Stężenie ghreliny w osoczu chorych z niedoczynnością 
tarczycy (z zapaleniem tarczycy typu Hashimoto lub po leczeniu 
radiojodem) przed (ghrelin 1) i po leczeniu (ghrelin 2)
Figure 4. Plasma ghrelin levels in hyperthyroid patients before 
(ghrelin 1) and after treatment (ghrelin 2)
Rycina 4. Stężenie ghreliny w osoczu chorych z nadczynnością 
tarczycy przed (ghrelin 1) i po leczeniu (ghrelin 2)
Discussion
Since food intake and body weight are the main factors 
regulating ghrelin secretion, we might have expected low 
ghrelin concentrations in hypothyroid patients, who usu-
ally gain weight, and high ghrelin level in hyperthyroid 
patients, who complain of increased appetite and weight 
loss. However, our results are compatible with most pre-
vious studies, that also revealed a high plasma ghrelin 
concentration in hypothyroid patients [34–36] and low 
ghrelin level in hyperthyroid patients [34, 36–38, 43–47].
The possible explanation for such results requires 
a thorough analysis of metabolic disturbances in pa-
tients with thyroid dysfunction. It is worth noting that, 
despite increased body weight, hypothyroidism is not 
a state of positive energy balance. Thyroid hormones 
insufficiency does not permit for appropriate use of 
energy resources. This situation can be compared to 
starvation, when authentic energy substrates deficiency 
is observed. Thus, hypothyroidism may be considered 
as a condition of negative energy balance, such as ano-
rexia nervosa, bulimia and cachexia.
Moreover, previous studies revealed that chronic 
starvation is accompanied by high ghrelin level and 
low triiodothyronine concentration [21–23, 49]. Analys-
ing metabolic disturbances not resulting from thyroid 
dysfunction, such hormonal changes can be explained 
as two ways of energy saving. Starving increases ghre-
lin secretion to stimulate prometabolic action, and low 
thyroid hormones level reduces energy expenditure.
In hypothyroidism, thyroid gland is not able to 
respond to metabolic changes in an appropriate way 
and ghrelin may act as one of the factors compensating 
energy balance disturbances.
In our study, the ghrelin level was noticeably high in 
patients with severe hypothyroidism due to Hashimoto’s 
thyroiditis or after radioiodine treatment. In patients after 
total thyreoidectomy with hypothyroidism induced by 
4-week L-thyroxine withdrawal, plasma ghrelin level 
did not differ from values observed in the control group. 
The difference between these groups could be explained 
by the severity of energy balance disorders. The patients 
with hypothyroidism due to Hashimoto’s thyroiditis or 
after radioiodine treatment had been developing the 
clinical symptoms over a long period of time. Advanced 
metabolic changes in this group resulted in considerably 
increased ghrelin production, and appropriate treat-
ment with L-thyroxine normalised metabolic rate and 
decreased plasma ghrelin level. The patients after total 
thyroidectomy were examined after 4-week L-thyroxine 
withdrawal. Such short discontinuation of hormonal 
therapy was not able to induce serious metabolic ab-
normalities. Thus, the clinical image of this group was 
definitely better and their plasma ghrelin level, although 
slightly tending to increase, was not significantly higher 
than in the control group.
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Metabolic disturbances could also be responsible for 
plasma ghrelin changes in hyperthyroid patients, whose 
metabolism rate, energy expenditure and thermogenesis 
are considerably increased. In this situation plasma ghrelin 
reduction may be associated with a transition to a more en-
ergy-efficient state, as previously suggested by Riis et al. [43].
Our study revealed that ghrelin correlated positively 
with TSH and negatively with fT3 and fT4 levels. Previously, 
Kluge et al. demonstrated that exogenous ghrelin increases 
fT4 and decreases TSH level in humans [50]. These obser-
vations additionally support the hypothesis of possible 
compensatory role of ghrelin in thyroid dysfunction.
Nevertheless, plasma ghrelin changes may also 
result from other factors. It is important to underline 
kidney dysfunction associated with thyroid disorders 
[51], what may obviously influence ghrelin elimination.
It is worth noting that acylated ghrelin circulates in 
plasma bounded by lipoproteins [52]. Thyroid dysfunc-
tion may alter cholesterol fractions, and this could be 
another possible explanation for plasma ghrelin changes 
in hyper- and hypothyroidism.
Previous studies have suggested the influence of in-
sulin level on ghrelin concentration in thyroid disorders 
[37, 43, 46]. High insulin level observed in hyperthyroid 
patients due to insulin resistance was suspected to de-
crease ghrelin release.
The analysis of obestatin changes in thyroid dysfunc-
tion revealed significantly lower peptide concentra-
tion in hyperthyroid patients. We did not observe any 
differences between hypothyroid groups and healthy 
subjects. Furthermore, obestatin correlated positively 
with TSH and negatively with free thyroid hormones. It 
is still unclear whether obestatin is a biologically active 
peptide. However, we cannot exclude that obestatin 
released together with ghrelin modulates its activity, 
what has been suggested by Zizzari et al. [53].
Since ghrelin and obestatin have been shown to 
derive from the same precursor, the studies usually 
revealed parallel changes of both peptides concentra-
tions [32, 36]. However, recent studies have shown that 
ghrelin and obestatin may be produced independently 
and alternative transcription of the preproghrelin gene 
could lead to an excess of one of the sibling peptides [54].
In our study, ghrelin and obestatin levels correlated 
positively in the whole study group, which rather con-
firms the common origin of both peptides. Moreover, 
such an observation probably disproves the primary 
hypothesis of opposite biological effects of ghrelin and 
obestatin, because in this case the rise of one peptide 
should rather cause the decrease of the other.
Ghrelin and obestatin plasma levels are technically 
difficult to assess [48]. However, it is worth the effort 
to conduct further studies considering their biological 
function in humans.
Conclusions
Plasma ghrelin changes in thyroid dysfunction may 
indicate a compensatory role of this peptide in meta-
bolic disturbances. In a state of severe hypothyroidism, 
high ghrelin concentration may lead to appropriate 
use of energy resources. In hyperthyroidism, which is 
accompanied by increased metabolic rate and energy ex-
penditure, low ghrelin level may be associated with the 
transition to a more energy-efficient state, as previously 
suggested by Riis et al. [43]. The positive correlation 
between ghrelin and obestatin concentrations may sug-
gest a modulatory role of obestatin in these processes.
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